Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Amvuttra Key to Alnylam Japan’s 25%-Plus CAGR Goal through 2030
RNAi specialist Alnylam Japan is targeting a compound annual growth rate (CAGR) of at least 25% from 2026 through 2030, with Amvuttra (vutrisiran) expected to serve as a key growth driver following its label expansion into transthyretin amyloid cardiomyopathy (ATTR-CM).…
To read the full story
Related Article
BUSINESS
- OB-GYN Chief Hopes for April 2027 NIP Addition of RSV Antibodies
September 30, 2026
- Toho, Reprocell Tie Up on Cell Therapy Distribution in Japan
September 30, 2026
- Marubeni Pharma Launches OAB Drug Gemtesa in Taiwan
September 29, 2026
- Taisho Pulls Plug on Clarith Tablets, Shifts to AG
September 29, 2026
- Tanabe Licenses Anti-IL-33 Antibody to Tolerance
September 29, 2026
The development of Boehringer Ingelheim’s survodutide is gathering pace, putting the GLP-1/glucagon receptor agonist in contention to become the next…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…